Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Conditions
Interventions
Tirzepatide
Semaglutide
Locations
127
United States
Cahaba Research
Birmingham, Alabama, United States
Syed Research Consultants Llc
Sheffield, Alabama, United States
National Research Institute - Huntington Park
Huntington Park, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
National Research Institute - Huntington Park
Panorama City, California, United States
Start Date
July 30, 2019
Primary Completion Date
January 28, 2021
Completion Date
February 15, 2021
Last Updated
February 14, 2022
NCT07232537
NCT06815081
NCT06003153
NCT06278207
NCT07051005
NCT07296484
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions